Abstract:FTY720 is a synthetic analogue of sphingosine 1‐phosphate. It is currently used to treat multiple sclerosis and has recently been approved for use in adolescents. The aim of this study was to investigate how FTY720 alters the lipid composition of the brain of adolescent mice. Three weeks of chronic FTY720 treatment caused an up‐regulation of 99 lipid species in the mouse hippocampus, including several oxidised phosphatidylcholines, whereas only 3 lipid species of the phosphatidic acid class were down‐regulated. Our study presents novel insight into FTY720's molecular mechanism of action in the central nervous system. FST, forced swim test; LC‐MS/MS, liquid chromatography–tandem mass spectrometry; MUFAs, monounsaturated fatty acids; MWM, Morris water maze; OFT, open field test; PCOH, hydroxy‐phosphatidylcholine; PND, postnatal day; PUFAs, polyunsaturated fatty acids; S1P, sphingosine 1‐phosphate; S1PR, sphingosine 1‐phosphate receptor. The small‐molecule drug, FTY720 (fingolimod), is a synthetic sphingosine 1‐phosphate (S1P) analogue currently used to treat relapsing–remitting multiple sclerosis in both adults and children. FTY720 can cross the blood–brain barrier (BBB) and, over time, accumulate in lipid‐rich areas of the central nervous system (CNS) by incorporating into phospholipid membranes. FTY720 has been shown to enhance cell membrane fluidity, which can modulate the functions of glial cells and neuronal populations involved in regulating behaviour. Moreover, direct modulation of S1P receptor‐mediated lipid signalling by FTY720 can impact homeostatic CNS physiology, including neurotransmitter release probability, the biophysical properties of synaptic membranes, ion channel and transmembrane receptor kinetics, and synaptic plasticity mechanisms. The aim of this study was to investigate how chronic FTY720 treatment alters the lipid composition of CNS tissue in adolescent mice at a key stage of brain maturation. We focused on the hippocampus, a brain region known to be important for learning, memory, and the processing of sensory and emotional stimuli. Using mass spectrometry‐based lipidomics, we discovered that FTY720 increases the fatty acid chain length of hydroxy‐phosphatidylcholine (PCOH) lipids in the mouse hippocampus. It also decreases PCOH monounsaturated fatty acids (MUFAs) and increases PCOH polyunsaturated fatty acids (PUFAs). A total of 99 lipid species were up‐regulated in the mouse hippocampus following 3 weeks of oral FTY720 exposure, whereas only 3 lipid species were down‐regulated. FTY720 also modulated anxiety‐like behaviours in young mice but did not affect spatial learning or memory formation. Our study presents a comprehensive overview of the lipid classes and lipid species that are altered in the hippocampus following chronic FTY720 exposure and provides novel insight into cellular and molecular mechanisms that may underlie the therapeutic or adverse effects of FTY720 in the central nervous system.

Actions of FTY720 (Fingolimod), a Sphingosine-1-Phosphate Receptor Modulator, on Delayed-Rectifier K+ Current and Intermediate-Conductance Ca2+-Activated K+ Channel in Jurkat T-Lymphocytes

FTY720 mediates activation suppression and G 0 /G 1 cell cycle arrest in a concanavalin A-induced mouse lymphocyte pan-activation model

Fingolimod Targets Cerebral Endothelial Activation To Block Leukocyte Recruitment In The Central Nervous System

Prophylactic administration of fingolimod (FTY720) ameliorated experimental autoimmune myasthenia gravis by reducing the number of dendritic cells, follicular T helper cells and antibody-secreting cells

Pharmacological Effects of FTY720 and its Derivatives

Fingolimod Suppresses the Proinflammatory Status of Interferon-γ-Activated Cultured Rat Astrocytes

FTY720 Alleviates Coxsackievirus B3‐induced Myocarditis and Inhibits Viral Replication Through Regulating Sphingosine 1‐phosphate Receptors and AKT/caspase‐3 Pathways

Diffusion Tensor Imaging Detects Treatment Effects of FTY720 in Experimental Autoimmune Encephalomyelitis Mice

Immunomodulatory drug FTY720 induces regulatory CD4+CD25 + T cells in vitro

FTY720 requires vitamin B12-TCN2-CD320 signaling in astrocytes to reduce disease in an animal model of multiple sclerosis

The emerging role of FTY720 as a sphingosine 1‐phosphate analog for the treatment of ischemic stroke: The cellular and molecular mechanisms

FTY720 Suppresses Pathogenic Retinal Müller Cell Activation and Chronic Progression by Inhibiting the Mtor/nf-Κb Signaling Pathway and Regulating Autophagy.

The functional antagonist of sphingosine-1-phosphate, FTY720, impairs gut barrier function

FTY720 induces non-canonical phosphatidylserine externalization and cell death in acute myeloid leukemia

The Effects of the S1P Receptor Agonist Fingolimod (FTY720) on Central and Peripheral Myelin in Twitcher Mice

Effect of Fingolimod on Neural Stem Cells: A Novel Mechanism and Broadened Application for Neural Repair.

FTY720 Suppresses Interleukin‐1β‐induced Secretory Phospholipase A2 Expression in Renal Mesangial Cells by a Transcriptional Mechanism

FTY720 for Cancer Therapy (Review)

Effect of FTY720 on Lymphocytes Proliferation and Apoptosis of in Vitro Mixed Lymphocytes Reaction

FTY720 ameliorates murine sclerodermatous chronic graft-versus-host disease by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin.

The sphingosine 1‐phosphate analogue, FTY720, modulates the lipidomic signature of the mouse hippocampus